SARcode Bioscience Inc.
USPTO PatentsView assignee record - 15 granted patents across 9 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Sarcode ranks #19,111 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 9 technology areas.
- #19,111
- of 49,997 US assignees by volume
- 20th percentile
- by Innovation Score (26.3/100)
- 10.3
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R19111 · US Corporation #19,111 · 15 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 15 grants
- MID-PACK #19,111/49,997
- PHOTO-FINISH Saic Motor
- CPC-NARROW C07D · 9 areas
- INNOV-THIN 26.3/100
- CLAIMS-PAR 10.3 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Saic Motor Corporation Limited (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Sarcode’s 26.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Sarcode
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- SARcode Bioscience · this assignee 26
SARcode Bioscience · this assignee
26 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Sarcode's Innovation Score is 26.3/100 (20th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Sarcode?
Each dot is one of Sarcode’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sarcode’s own 10.3 claims/patent is at or below the 13.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Sarcode's grants concentrate
SARcode Bioscience Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (6 grants) versus a trough of 1 in 2017. By volume, Sarcode sits between Saic Motor Corporation Limited and Screening Room Media, Inc..
Who files at SARcode's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Saic Motor
Saic Motor Corporation Limited
15 patents
- Saife
Saife, Inc.
15 patents
- Saint-gobain Ecop…
Saint-gobain Ecophon AB
15 patents
- Sankei Giken Kogyo
Sankei Giken Kogyo Co., Ltd.
15 patents
- Sawafuji Electric
Sawafuji Electric Co., Ltd.
15 patents
- Sawai Pharmaceuti…
Sawai Pharmaceutical Co., Ltd.
15 patents
- Scanadu Incorpora…
Scanadu Incorporated
15 patents
- Screening Room Me…
Screening Room Media, Inc.
15 patents
- Sarcode Bioscience ◀
SARcode Bioscience Inc.
15 patents
What this shows SARcode holds 15 patents at rank #19,103, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near SARcode
By rank, the assignees closest to #19,103 in granted patent volume.
- Saic Motor Corporation Limited #19,099 · 15 patents
- Saife, Inc. #19,100 · 15 patents
- Saint-gobain Ecophon AB #19,101 · 15 patents
- Sankei Giken Kogyo Co., Ltd. #19,102 · 15 patents
- Sawafuji Electric Co., Ltd. #19,104 · 15 patents
- Sawai Pharmaceutical Co., Ltd. #19,105 · 15 patents
- Scanadu Incorporated #19,106 · 15 patents
- Screening Room Media, Inc. #19,107 · 15 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in SARcode's primary technology class.
Sarcode's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
26 20th percentile higher than 20% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 6 | 40.0% |
| 2016 | 3 | 20.0% |
| 2017 | 1 | 6.7% |
| 2018 | 2 | 13.3% |
| 2019 | 3 | 20.0% |
Which technologies does SARcode Bioscience Inc. patent most?
Top 9 of 9 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
SARcode Bioscience Inc.'s patent record in context - here's where to go next.
- SARcode Bioscience Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #19,111 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare SARcode Bioscience Inc. against Saic Motor Corporation Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 26.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.